British Journal of Radiology · 1984 · 33 citations · 8 references
MedicineOncologyRadiation OncologyGynecologic OncologyMedical OncologyOncology PharmacotherapyCervical CancerCytotoxic ChemotherapyGynecologic Cancer PharmacotherapyGynecologic Cancer RadiotherapyMalignant NeoplasmsRadiation TherapyAdenocarcinoma Of The CervixCervical Cancer RadiotherapyDisease-free Survival AnalysisDisease-free Survival AssessmentInterim AnalysisRadiation Sensitization
153 patients from 13 centres were entered into a randomised controlled trial of the hypoxic cell sensitiser , misonidazole, in the radiotherapy of Stage III carcinoma of the uterine cervix. In an interim analysis at a time when follow-up periods extended from 9 to 45 months, no benefit in survival or local tumour control has been demonstrated. When disease-free survival of all cases was considered it was found that the younger patients did less well than the older patients and that the greater the immediate response to radiotherapy the longer was the duration of survival free of disease.
8
Clinical testing of the radiosensitizer Ro 07-0582: Experience with multiple doses
Stanley Dische, Megan I. Saunders, M E Lee et al. · British Journal of Cancer · 1977 · 259 citations